As of 2025-10-16, the EV/EBITDA ratio of Esperion Therapeutics Inc (ESPR) is -20.40. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. ESPR's latest enterprise value is 720.24 mil USD. ESPR's TTM EBITDA according to its financial statements is -35.31 mil USD. Dividing these 2 quantities gives us the above ESPR EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 7.5x - 14.1x | 11.0x |
| Forward P/E multiples | 12.5x - 23.3x | 17.2x |
| Fair Price | (2.36) - (0.70) | (1.89) |
| Upside | -193.6% - -127.6% | -174.9% |
| Date | EV/EBITDA |
| 2025-10-15 | -20.40 |
| 2025-10-14 | -21.42 |
| 2025-10-13 | -21.54 |
| 2025-10-10 | -20.45 |
| 2025-10-09 | -20.03 |
| 2025-10-08 | -20.68 |
| 2025-10-07 | -23.65 |
| 2025-10-06 | -23.82 |
| 2025-10-03 | -24.85 |
| 2025-10-02 | -22.57 |
| 2025-10-01 | -22.57 |
| 2025-09-30 | -21.14 |
| 2025-09-29 | -21.08 |
| 2025-09-26 | -21.14 |
| 2025-09-25 | -20.62 |
| 2025-09-24 | -19.88 |
| 2025-09-23 | -20.17 |
| 2025-09-22 | -20.34 |
| 2025-09-19 | -21.20 |
| 2025-09-18 | -21.71 |
| 2025-09-17 | -21.54 |
| 2025-09-16 | -21.82 |
| 2025-09-15 | -21.88 |
| 2025-09-12 | -22.22 |
| 2025-09-11 | -21.94 |
| 2025-09-10 | -20.85 |
| 2025-09-09 | -20.51 |
| 2025-09-08 | -20.34 |
| 2025-09-05 | -21.31 |
| 2025-09-04 | -20.45 |
| 2025-09-03 | -19.88 |
| 2025-09-02 | -19.25 |
| 2025-08-29 | -18.68 |
| 2025-08-28 | -18.63 |
| 2025-08-27 | -18.46 |
| 2025-08-26 | -18.51 |
| 2025-08-25 | -18.28 |
| 2025-08-22 | -18.40 |
| 2025-08-21 | -18.17 |
| 2025-08-20 | -17.71 |
| 2025-08-19 | -17.66 |
| 2025-08-18 | -18.00 |
| 2025-08-15 | -17.71 |
| 2025-08-14 | -17.83 |
| 2025-08-13 | -17.08 |
| 2025-08-12 | -16.23 |
| 2025-08-11 | -16.54 |
| 2025-08-08 | -16.69 |
| 2025-08-07 | -16.34 |
| 2025-08-06 | -16.97 |